| Recruiting | Differentiating the Invasiveness of Lung Adenocarcinoma by Dual Energy CT Parameter NCT06441357 | Tang-Du Hospital | — |
| Terminated | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors NCT06299163 | Numab Therapeutics AG | Phase 1 |
| Unknown | Multi-omics Analysis to Characterize the Invasive Evolution of Pulmonary Subsolid Nodules NCT06215885 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | — |
| Recruiting | A Study of Tumor-Treating Fields (TTFields) in People With Lung Adenocarcinoma NCT05764954 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Expr NCT05292859 | Alaunos Therapeutics | — |
| Recruiting | A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma NCT05456256 | Lantern Pharma Inc. | Phase 2 |
| Withdrawn | CISH Inactivated TILs in the Treatment of NSCLC NCT05566223 | Intima Bioscience, Inc. | Phase 1 / Phase 2 |
| Recruiting | Using Biomarkers for Diagnosis, Risk Stratification of Post -Treatment Recurrence and Long-Term Surveillance o NCT05665504 | H. Lee Moffitt Cancer Center and Research Institute | — |
| Recruiting | RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase NCT04105270 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Unknown | Prognostic Value of Lung Cancer MicroAnatomy in 3D NCT05565677 | Aristotle University Of Thessaloniki | — |
| Recruiting | APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innov NCT05550961 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | — |
| Terminated | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors NCT05194735 | Alaunos Therapeutics | Phase 1 / Phase 2 |
| Completed | Evaluation of Correlations Between Radiologic Features and Pathologic Subtypes of GGO LUAD Via WMS (ECTOP-1011 NCT05252676 | Fudan University | — |
| Unknown | ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas NCT05079022 | Peking University People's Hospital | Phase 1 / Phase 2 |
| Unknown | Comparative Genomic Profiling of Lung Adenocarcinoma in Asians and Caucasians: A Propensity Matched Analysis NCT04692935 | Jun Wang | — |
| Completed | Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib NCT04770688 | Shanghai Chest Hospital | Phase 1 / Phase 2 |
| Active Not Recruiting | Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors NCT04557449 | Pfizer | Phase 2 |
| Recruiting | Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients NCT04566432 | Geneplus-Beijing Co. Ltd. | — |
| Completed | Comparison of Robotic Arm-assisted PET/CT-guided Lung Biopsy With PET Fused CT- Fluoroscopy-guided Lung Biopsy NCT05245630 | Post Graduate Institute of Medical Education and Research, Chandigarh | — |
| Withdrawn | Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma NCT03361319 | Royal Marsden NHS Foundation Trust | Phase 1 / Phase 2 |
| Completed | HRCT in Prediction of Tumor Invasion in GGO Lung Adenocarcinoma (ECTOP-1008) NCT04165759 | Fudan University | — |
| Unknown | Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study NCT04122833 | Konkuk University Medical Center | — |
| Terminated | LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small NCT04027946 | National Cancer Institute (NCI) | Phase 2 |
| Completed | The Detection of EGFR Mutations in Liquid Based Cytology Samples NCT04086680 | Royal Cornwall Hospitals Trust | — |
| Recruiting | Bioimpedance Analysis in Perioperative Assessment in Thoracic Surgery NCT06796816 | Azienda USL Reggio Emilia - IRCCS | N/A |
| Unknown | Targeted Stem Cells Expressing TRAIL as a Therapy for Lung Cancer NCT03298763 | University College, London | Phase 1 / Phase 2 |
| Completed | To Compare Efficacy and Safety of CT-P16 and European Union-Approved Avastin as First-Line Treatment for Metas NCT03676192 | Celltrion | Phase 3 |
| Unknown | The Tracking Molecular Evolution for NSCLC (T-MENC) Study NCT03838588 | Geneplus-Beijing Co. Ltd. | — |
| Terminated | An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combi NCT03371381 | Janssen Research & Development, LLC | Phase 1 / Phase 2 |
| Completed | Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (N NCT03184571 | BerGenBio ASA | Phase 2 |
| Completed | Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China NCT03059641 | Geneplus-Beijing Co. Ltd. | — |
| Unknown | ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC NCT02946216 | First People's Hospital of Hangzhou | — |
| Unknown | Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma NCT02804646 | Anhui Provincial Hospital | Phase 4 |
| Active Not Recruiting | The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-T NCT02493582 | The First People's Hospital of Changzhou | Phase 2 |
| Completed | An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors NCT02616211 | Mayo Clinic | — |
| Completed | SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma NCT01362790 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Vaccine Treatment for Advanced Non-Small Cell Lung Cancer NCT00073398 | NewLink Genetics Corporation | Phase 1 / Phase 2 |